Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 3:45 pm Purchase |
2022-12-31 | 13G | Trevi Therapeutics, Inc. TRVI |
Fairmount Funds Management LLC | 6,018,465 9.900% |
2,258,955 (+60.09%) |
Filing History |
| 2023-02-14 1:37 pm Purchase |
2022-12-31 | 13G | Trevi Therapeutics, Inc. TRVI |
Armistice Capital, LLC | 3,147,200 4.990% |
446,401 (+16.53%) |
Filing History |
| 2023-02-14 1:18 pm Purchase |
2022-12-31 | 13G | Trevi Therapeutics, Inc. TRVI |
VIKING GLOBAL INVESTORS LP | 6,162,362 9.990% |
177,628 (+2.97%) |
Filing History |
| 2023-02-10 4:25 pm Sale |
2022-12-31 | 13G | Trevi Therapeutics, Inc. TRVI |
TPG GP A, LLC | 0 0.000% |
-4,824,883 (Position Closed) |
Filing History |
| 2023-02-10 4:00 pm Purchase |
2022-12-31 | 13G | Trevi Therapeutics, Inc. TRVI |
Rubric Capital Management LP | 5,684,420 9.490% |
5,684,420 (New Position) |
Filing History |
| 2022-10-07 5:29 pm Purchase |
2022-09-27 | 13G | Trevi Therapeutics, Inc. TRVI |
VIKING GLOBAL INVESTORS LP | 5,984,734 9.990% |
5,984,734 (New Position) |
Filing History |
| 2022-10-07 2:51 pm Purchase |
2022-10-05 | 13G | Trevi Therapeutics, Inc. TRVI |
Frazier Life Sciences Public Fund, L.P. | 6,663,590 11.400% |
2,847,131 (+74.60%) |
Filing History |
| 2022-04-25 5:04 pm Purchase |
2022-04-11 | 13D | Trevi Therapeutics, Inc. TRVI |
New Enterprise Associates 16, L.P. | 14,370,376 42.500% |
6,580,526 (+84.48%) |
Filing History |
| 2022-04-21 4:05 pm Purchase |
2022-04-11 | 13G | Trevi Therapeutics, Inc. TRVI |
Venrock Healthcare Capital Partners II, L.P. | 3,668,334 9.990% |
3,668,334 (New Position) |
Filing History |
| 2022-04-21 10:00 am Purchase |
2022-04-11 | 13G | Trevi Therapeutics, Inc. TRVI |
Fairmount Funds Management LLC | 3,759,510 9.900% |
3,759,510 (New Position) |
Filing History |
| 2022-04-18 1:32 pm Purchase |
2022-04-11 | 13G | Trevi Therapeutics, Inc. TRVI |
Frazier Life Sciences Public Fund, L.P. | 3,816,459 10.000% |
3,816,459 (New Position) |
Filing History |
| 2022-04-08 10:41 am Purchase |
2022-03-30 | 13G | Trevi Therapeutics, Inc. TRVI |
MAI Capital Management | 1,541,471 5.000% |
1,541,471 (New Position) |
Filing History |
| 2022-03-09 5:09 pm Purchase |
2022-02-28 | 13G | Trevi Therapeutics, Inc. TRVI |
Rosalind Advisors, Inc. | 2,185,664 8.500% |
2,185,664 (New Position) |
Filing History |
| 2022-03-09 11:18 am Purchase |
2022-03-07 | 13G | Trevi Therapeutics, Inc. TRVI |
Steven Michael Oliveira | 1,340,000 5.180% |
1,340,000 (New Position) |
Filing History |
| 2022-02-14 5:16 pm Purchase |
2021-12-31 | 13G | Trevi Therapeutics, Inc. TRVI |
Armistice Capital, LLC | 2,700,799 9.990% |
2,700,799 (New Position) |
Filing History |
| 2022-02-11 4:16 pm Purchase |
2022-01-12 | 13G | Trevi Therapeutics, Inc. TRVI |
TPG GP A, LLC | 4,824,883 18.700% |
4,824,883 (New Position) |
Filing History |
| 2022-01-26 4:15 pm Unchanged |
2021-12-31 | 13G | Trevi Therapeutics, Inc. TRVI |
Lundbeckfond Invest A/S | 1,151,544 4.500% |
0 (Unchanged) |
Filing History |
| 2021-11-02 09:09 am Purchase |
2021-10-18 | 13D | Trevi Therapeutics, Inc. TRVI |
New Enterprise Associates 16, L.P. | 7,789,850 36.100% |
1,851,852 (+31.19%) |
Filing History |
| 2021-02-12 4:54 pm Sale |
2020-12-31 | 13G | Trevi Therapeutics, Inc. TRVI |
TPG Group Holdings (SBS) Advisors Inc. | 4,824,883 26.200% |
-1,499,436 (-23.71%) |
Filing History |